BIOADAPTIVES, INC. (BDPT) Form 10-Q — Aug 19, 2026
BioAdaptives' 10-Q for the quarter ended June 30, 2026 discloses substantial doubt about the company's ability to continue as a going concern. Cash fell to $29,221 from $158,445 at year-end 2025 while the company burned $129,224 in operating cash over six months, leaving a $1,766,107 stockholders' deficit against a $10,682,200 accumulated deficit and $1,844,874 in current liabilities. The company reported Q2 net income of $150,090 and six-month net income of $39,004, but the swing to profit came almost entirely from a $446,730 non-cash gain on derivative liabilities rather than operations. Quarterly revenue was just $4,988 (six months: $10,502) against $202,795 of six-month interest expense.
Key figures
- Eps
- Q2 basic $0.01 / diluted $(0.00); six-month basic $0.00 / diluted $(0.00)
- Revenue
- 4988
- Net Income
- 150090
- Total Debt
- Convertible notes $490,629 carrying value ($607,250 principal) plus notes payable $32,096
- Cash Position
- 29221
- Total assets
- 78767
- Q2 2025 revenue
- 3219
- Q2 2026 revenue
- 4988
- Ceo annual salary
- 300000
- Accumulated deficit
- 10682200
- Derivative liabilities
- 1050397
- Six month 2026 revenue
- 10502
- Six month 2026 net income
- 39004
- Total current liabilities
- 1844874
- Six month interest expense
- 202795
- Q2 derivative fair value gain
- 446730
- Shares outstanding june 30 2026
- 36595174
- Convertible note conversion terms
- 60-65% of lowest traded price over 20 trading days
- Excluded potential dilutive securities
- 540209133
- Shares outstanding aug 13 2026 cover page
- 196926762
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.